Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: A single-arm clinical trial

Kazuki Takada, Yoshinori Katada, Satoshi Ito, Taichi Hayashi, Jun Kishi, Kenji Itoh, Hiroyuki Yamashita, Michito Hirakata, Kimito Kawahata, Atsushi Kawakami, Norihiko Watanabe, Tatsuya Atsumi, Yoshinari Takasaki, Nobuyuki Miyasaka

Research output: Contribution to journalArticle

Abstract

Objective: Interstitial pneumonia is common and has high short-term mortality in patients with PM and DM despite glucocorticoid (GC) treatment. Retrospective studies suggested that the early use of immunosuppressive drugs with GCs might improve its short-term mortality. Methods: A multicentre, single-arm, 52-week-long clinical trial was performed to test whether the initial combination treatment with tacrolimus (0.075 mg/kg/day, adjusted for the target whole-blood trough levels between 5 and 10 ng/ml) and GCs (0.6-1.0 mg/kg/day of prednisolone followed by a slow taper) improves short-term mortality of PM/DM-interstitial pneumonia patients. The primary outcome was overall survival. We originally intended to compare, by using propensity-score matching, the outcome data of clinical trial patients with that of historical control patients who were initially treated with GCs alone. Results: The 52-week survival rate with the combination treatment (N = 26) was 88.0% (95% CI, 67.3, 96.0). Safety profiles of the combination treatment were consistent with those known for tacrolimus and high-dose GCs individually. Serious adverse events occurred in 11 patients (44.0%), which included four opportunistic infections. Only 16 patients, including only 1 deceased patient, were registered as historical controls, which precluded meaningful comparative analysis against the clinical trial patients. Conclusion: Our study provided findings which suggest that initial treatment with tacrolimus and GCs may improve short-term mortality of PM/DM-interstitial pneumonia patients with manageable safety profiles. This was the first prospective clinical investigation conducted according to the Good Clinical Practice Guideline of the International Conference on Harmonization for the treatment of this potentially life-threatening disease. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00504348.

Original languageEnglish
Pages (from-to)1084-1093
Number of pages10
JournalRheumatology (United Kingdom)
Volume59
Issue number5
DOIs
Publication statusPublished - 2020 May 1

Keywords

  • dermatomyositis
  • interstitial lung disease
  • interstitial pneumonia
  • polymyositis
  • tacrolimus

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: A single-arm clinical trial'. Together they form a unique fingerprint.

  • Cite this

    Takada, K., Katada, Y., Ito, S., Hayashi, T., Kishi, J., Itoh, K., Yamashita, H., Hirakata, M., Kawahata, K., Kawakami, A., Watanabe, N., Atsumi, T., Takasaki, Y., & Miyasaka, N. (2020). Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: A single-arm clinical trial. Rheumatology (United Kingdom), 59(5), 1084-1093. https://doi.org/10.1093/rheumatology/kez394